Vimseltinib (DCC-3014) is a highly selective small-molecule inhibitor of colony-stimulating factor 1 receptor (CSF1R), with the molecular formula C₂₃H₂₅N₇O₂ and a molecular weight of 431.49 g/mol . It targets CSF1R, a receptor tyrosine kinase involved in the survival, proliferation, and differentiation of monocytes, macrophages, and osteoclasts.
By inhibiting CSF1R signaling, Vimseltinib interferes with macrophage-related pathways and modulates the tumor microenvironment (TME). This mechanism makes it a valuable compound for investigating tumor-associated macrophages (TAMs), immune regulation, and cancer-related signaling pathways.
Vimseltinib has been investigated in oncology research, particularly in tenosynovial giant cell tumor (TGCT), where CSF1R signaling plays an important role in disease progression. It is a useful research compound for studying CSF1R inhibition, macrophage biology, and potential targeted therapeutic strategies in oncology.
关键字： Antitumor compound;DCC-3014;CSF1R inhibitor;CSF-1R inhibitor;
杭州埃米尔生物技术有限公司位于浙江省杭州市钱塘区下沙街道安和药谷，立足杭州生物医药产业集聚区位优势，专注深耕ADC/XDC 生物偶联技术研发服务、医药小分子中间体定制合成两大核心业务，是聚焦抗体偶联药物上下游研发配套的专业化生物技术初创企业，面向药企、CRO 公司、高校科研院所提供从工艺开发、样品合成到质控分析的一站式技术外包解决方案。